Lates News

According to AI Quick News, Huayuan Securities released a research report on August 22, giving a buy rating to Jianmin Group (600976.SH). The reasons for the rating mainly include: 1) the pharmaceutical industry has shown remarkable growth, and the structure of the pharmaceutical business continues to improve; 2) brand strategy driving the rapid development of the OTC product line; 3) acceleration in the volume of traditional Chinese medicine innovative drugs, with continuous increase in research and development investment. (Daily Economic News)